Know Cancer

or
forgot password


Phase 1
N/A
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information


Inclusion Criteria:



- histopathological or cytopathology diagnosis of malignancy

- heart, liver and renal function is normal

- Expected survival time is more than 3 months

- Signed informed consent

exclusion Criteria:

- non cancer patient

- accepted elemene administration in 1 month

- Expected survival time is less than 3 months

- no Signed informed consent

- heart, liver and renal function is abnormal

Type of Study:

Observational

Study Design:

Observational Model: Case-Only

Outcome Measure:

blood and cerebrospinal fluid concentration

Outcome Time Frame:

0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose

Safety Issue:

No

Principal Investigator

liang xiaohua, phD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Huashan Hospital of Fudan University

Authority:

China: Ethics Committee

Study ID:

HSZL201001

NCT ID:

NCT01679847

Start Date:

September 2012

Completion Date:

June 2013

Related Keywords:

  • Cancer
  • Elemene
  • pharmacokinetics
  • Blood-brain barrier

Name

Location